英国第一季度商业投资总值年率终值 6.1%，前值由8.10%修正为1.8%。 ...

英国第一季度商业投资总值季率终值 3.9%，前值由5.90%修正为-1.9%。 ...

英国一季度商业投资总额季环比终值 3.91%，预期 5.8%，初值 5.9%。 ...

英国一季度商业投资总额同比终值 6.05%，预期 8.1%，初值 8.1%。 ...

以下文章来源于金融八卦女频道 ，作者月月 金融八卦女频道 . 有深度、有温度、有态度，在这里读懂财富。 其实明眼人都能看出来，李亚鹏要是复出拍戏，说不定还真能翻红，早日还清债务。但一心想做生意的 李亚鹏，可能很难从 " 商业大佬 " 的美梦中醒过来了。 文丨金融八卦女 作者：月月 李亚鹏又出来"洗白"了？ 最近，他突然在社交平台上发视频辟谣丽江项目失败，称做得挺好的： "在15年开盘，就是丽江销售的第一名，2020年、2021年还逆势卖了70个亿，赚肯定赚了，这10年光发 工资就发了几个小目标。" 乍一听这话，这不就是妥妥的"地产大亨"吗？但等等，几天前，李亚鹏两口子的剧情走向还是"哭 穷"啊！ 上个月，李亚鹏的第二任妻子——海哈金喜直播搬家，说家里经济状况不好，要缩减开支，他们不得不 从之前居住的大平层搬到一个普通小区的普通房子去。 01 为了当"地产大亨" 他背上了4000万的巨债 先来聊聊李亚鹏这个宣称"逆势卖了70个亿"的丽江地产项目。 众所周知，十多年前，房地产生意属于是闭着眼买块地都能发财的黄金年代，催生了一大批草莽出身的 地产大佬。 而那时已经沉迷经商的李亚鹏，也做起了"地产大亨"的美梦，200 ...

美联储理事Cook：预计特朗普政府的贸易政策和相关的不确定性将在短期内拖累生产率的增长，这可 能促使美联储在更长时间内维持政策利率不变。 由于生产率下降，潜在经济增速的下滑将带来更大的通胀压力。 在其他条件相同的情况下，较低的生产率可能会促使我支持在更长时间内将利率保持在较高水平。 由于企业不知道关税的最终水平或持续时间，贸易政策的不确定性可能会减少商业投资，从而影响生产 率。 如果保护主义贸易政策支持效率较低的公司，或者如果这些变化导致供应链中断，生产率也可能受到影 响。 人工智能可以在未来几年提高美国的生产率，潜在地抵消贸易政策的负面影响。 ...

美国里士满联储主席Barkin：消费者支出和商业投资依然非常稳健。 到目前为止，消费者信心与支出并不一致。 ...

Avadel Pharmaceuticals (AVDL) Q1 2025 Earnings Call May 07, 2025 08:00 AM ET Company Participants Austin Murtagh - Director of Investor Relations & External CommunicationsGregory Divis - CEOThomas McHugh - CFOAndrew Tsai - SVPMarc Goodman - Senior MD - NeuroscienceDi Zhao - Equity Research Associate - Biopharmaceuticals/Biotechnology Conference Call Participants David Amsellem - Sr. Research AnalystDavid Hoang - Director, Senior Analyst, BiotechnologyMyriam Belghiti - Equity Research AnalystAmi Fadia - Seni ...

Financial Data and Key Metrics Changes - The company reported net revenue of $52.5 million for Q1 2025, representing over 90% growth compared to Q1 2024, which had net revenue of $27.2 million [7][18] - Gross profit for Q1 2025 was $46.9 million, up from $25.7 million in the prior year [18] - The company raised its full-year revenue guidance to $255 million to $265 million from a previous range of $240 million to $260 million [17][19] Business Line Data and Key Metrics Changes - The company ended Q1 with 2,800 patients on LUMRIZE, reflecting 100% growth year-over-year [6] - There was a 50% increase in net new patients during Q1 compared to Q4 2024, with an addition of 300 patients [6] - The company expanded its sales force by 15% and doubled the size of its field reimbursement and nursing support teams, contributing to improved patient engagement and persistency [8][9][10] Market Data and Key Metrics Changes - The company is pursuing additional indications for LUMRIZE beyond narcolepsy, particularly idiopathic hypersomnia (IH), with an estimated 42,000 patients diagnosed and only one FDA-approved treatment currently available [11][12] - The company believes LUMRIZE has the potential to unlock significant market opportunities in IH, as prescribers express excitement about the prospect of prescribing it for this condition [11][12] Company Strategy and Development Direction - The company aims to achieve $1 billion in LUMRIZE revenue while expanding its impact to additional patient populations [15] - The company is focused on lifecycle management initiatives to maximize the potential of its once-at-bedtime formulation beyond narcolepsy [23] - The company is actively pursuing legal actions to protect its intellectual property and has a robust portfolio that extends protection until 2042 [24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the commercial investments made at the beginning of the year, which are expected to drive sustainable positive cash flow [23] - The company remains optimistic about its growth trajectory, despite potential industry-wide changes related to tariffs and policies impacting biotech [21] - Management highlighted the importance of maintaining financial discipline while scaling operations and expects continued revenue growth and cash flow improvement [19][20] Other Important Information - The company ended Q1 2025 with $66.5 million in cash, cash equivalents, and marketable securities [20] - The company reported a GAAP operating loss of $3 million for Q1, but adjusted operating income was positive at $2 million, marking the third consecutive quarter of positive adjusted operating income [20] Q&A Session Summary Question: Revised 2025 guidance and growth assumptions - Management confirmed that the first half of the year is expected to show sequential growth quarter over quarter, with a focus on improving key metrics [28][29] Question: Nature of the recent court ruling - Management indicated that the ruling was aligned with their base case scenario and provides a clear path to continue executing their plans for LUMRIZE [34][35] Question: Patient metrics and competitive landscape for IH - Management views the IH opportunity as highly untapped and believes LUMRIZE can successfully source patients from various segments, including those not currently treated with oxybate [40][41] Question: Discontinuation rates and updated guidance - Management reported a decrease in discontinuation rates from 14% in Q4 to a lower figure in Q1, contributing to increased confidence in their updated guidance [77][79] Question: Offensive lawsuits and timelines - Management elaborated on their offensive lawsuits against Jazz, asserting their intellectual property rights, and mentioned upcoming administrative steps in the litigation process [81][84]